The article reports on the valuation of the share price of Westminster, Colorado-based biopharmaceutical company, Myogen Inc. The company's positive clinical trial results have propelled its market valuation to predictable ranges. In September 2005, Myogen's stock reach 23.25 dollars per share. Its two most promising developmental drugs would seem to imply a 3.3 billion dollar market capitalization.